AR006518A1 - Esteres de derivados de 1,4-piperidina disustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y un procedimiento para su preparacion - Google Patents
Esteres de derivados de 1,4-piperidina disustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y un procedimiento para su preparacionInfo
- Publication number
- AR006518A1 AR006518A1 ARP970100789A ARP970100789A AR006518A1 AR 006518 A1 AR006518 A1 AR 006518A1 AR P970100789 A ARP970100789 A AR P970100789A AR P970100789 A ARP970100789 A AR P970100789A AR 006518 A1 AR006518 A1 AR 006518A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- alk
- cycloalkyl
- procedure
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 238000000034 method Methods 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical class FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- -1 hydroxy C1-6 alkyl Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invenciión se refiere a nuevos esteres de derivados de 1,4- piperidina disubstituida de fórmula I; las formas N-óxido, las sales de adiciónde ácidos farmacéuticamente aceptables de la misma, o las formas estereoquímicam enteisoméricas de la misma caracterizado porque R1 es alquiloxiC1-6, alqueniloxi C2-6 o alquiniloxi C2-6; R2 es hidrógeno o alquiloxi C1-6 o cuando R1 y R2 en conjunto pueden formar un radical bivalente de fórmula,cuando en dichos radicales bivalentes uno o dos átomos de hidrógeno pueden ser sustituídos con alquilo C1-6; R3 es hidrógeno o halo; L es cicloalquilo C3-6cicloalcanona C5-6 alquenilo CC2-6 sustituido opcionalmente con Ar o L es un radical de fórmula -Alk-R4, -Alk-NR5R6, 1-R64-p iperidinilo, Alk-X-R7, -Alk-Y-C--(=O)-R9, o Alk-Y-C(=O=-NR11R12, donde cada Alk es alcanodilo X1-12; R4 es hidrógeno o alquilsulfonilamino C1-6, cicloalquilo C3-6, cicloalcanona C5-6 di(Ar) metilo, Ar-oxi- o Het 1; R5 es hidrógeno, alquilo C1- 6; R6 es Het2, R7 es hidrógeno, alquilo C1-6, hidroxi alquilo C1-6, cicloalquilo C3-6, Ar o Het2, Xes O,S,SO2 o NR8, siendo R8 hidrógeno, alquilo C1-6 o AR; R9 es hidrógeno, alquilo C1-6, cicloalquilo C3-6, Ar, Ar alquilo C1-6, di (Ar)metilo, a lquiloxiC1-6 o hidroxi; Y es NR10 o un enlace directo; siendo dicho R10 hidrógeno, alquilo C1-6 o Ar; R11 y R12 son cada uno en forma independiente, hidrógeno,alquilo C1-6, cicloalquilo C3-6, Ar o Ar alquilo C1-6 o R11 y R12 en formacombin ada con R11 y R12 con carga de átomo de nitrógeno que pueden formar unanillo de pirrolidinilo o piperidinilo, ambos siendo opcionalment sustituidos con alquilo C1-6 amino o mono o di (alquilo C1-6) amino, o dichos R11 y R12combinado con R11y R12 c on carga de nitrógeno de R11 y R12 pueden formar un radical de piperazinilo o de 4-morfolinilo, ambos siendo opcionalmente
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96200525 | 1996-02-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR006518A1 true AR006518A1 (es) | 1999-09-08 |
Family
ID=8223729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100789A AR006518A1 (es) | 1996-02-29 | 1997-02-27 | Esteres de derivados de 1,4-piperidina disustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y un procedimiento para su preparacion |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US6291481B1 (es) |
| EP (1) | EP0885190B1 (es) |
| JP (1) | JP2000505461A (es) |
| KR (1) | KR100485148B1 (es) |
| AR (1) | AR006518A1 (es) |
| AT (1) | ATE239706T1 (es) |
| AU (1) | AU724401B2 (es) |
| DE (1) | DE69721742T2 (es) |
| ES (1) | ES2199341T3 (es) |
| ID (1) | ID17758A (es) |
| MY (1) | MY121632A (es) |
| TW (1) | TW445263B (es) |
| WO (1) | WO1997031897A1 (es) |
| ZA (1) | ZA971735B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW445263B (en) * | 1996-02-29 | 2001-07-11 | Janssen Pharmaceutica Nv | Novel esters of 1,4-disubstituted piperidine derivatives |
| TW570920B (en) * | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| GB0002312D0 (en) * | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
| US7065096B2 (en) * | 2000-06-23 | 2006-06-20 | Mips Technologies, Inc. | Method for allocating memory space for limited packet head and/or tail growth |
| CA2471729C (en) | 2002-01-16 | 2010-03-23 | Janssen Pharmaceutica N.V. | Prucalopride-n-oxide |
| KR20050122220A (ko) * | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
| ATE440825T1 (de) * | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| AU2004295058B9 (en) | 2003-11-20 | 2011-06-30 | Janssen Pharmaceutica N.V. | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| BRPI0416817A (pt) | 2003-11-20 | 2007-03-06 | Janssen Pharmaceutica Nv | 2-quinolinonas e 2-quinoxalinonas 7-fenilalquila substituìdas como inibidores da poli(adp-ribose)polimerase |
| WO2005092882A1 (en) * | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| BRPI0512790A (pt) | 2004-06-30 | 2008-04-08 | Janssen Pharmaceutica Nv | derivados de 2-alquil quinazolinona substituìdos como inibidores de parp |
| WO2006003148A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Quinazolinedione derivatives as parp inhibitors |
| NZ551799A (en) | 2004-06-30 | 2009-11-27 | Janssen Pharmaceutica Nv | Phthalazine derivatives as PARP inhibitors |
| DK2134691T3 (da) | 2007-03-08 | 2012-05-07 | Janssen Pharmaceutica Nv | Quinolinonderivativer som parp- og tank-inhibitorer |
| US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| ES2367760T3 (es) | 2008-03-27 | 2011-11-08 | Janssen Pharmaceutica, N.V. | Derivados de quinazolinona como inhibidores de la polimerización de la tubulina. |
| AU2009228943B2 (en) | 2008-03-27 | 2013-04-04 | Janssen Pharmaceutica Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors |
| WO2016149090A1 (en) * | 2015-03-13 | 2016-09-22 | Mironova Innovations, Llc | Nalpha, nalpha, nalpha-trialkyl histidine derivatives useful for the preparation of ergothioneine compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2116024A1 (en) | 1991-08-20 | 1993-03-04 | Francis David King | 5-ht4 receptor antagonists |
| SG49153A1 (en) * | 1991-09-12 | 1998-05-18 | Smithkline Beecham Plc | 5-HT4 receptor antagonists |
| NZ246915A (en) * | 1992-02-06 | 1996-05-28 | Smithkline Beecham Plc | Benzopyran, benzothiopyran and benzofuran derivatives, preparation and pharmaceutical compositions thereof |
| GB9219163D0 (en) * | 1992-09-10 | 1992-10-28 | Smithkline Beecham Plc | Pharmaceuticals |
| CA2146930A1 (en) | 1992-10-13 | 1994-04-28 | Francis David King | Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists |
| MX9306311A (es) | 1992-10-13 | 1994-04-29 | Smithkline Beecham Plc | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
| WO1994010174A1 (en) * | 1992-11-05 | 1994-05-11 | Smithkline Beecham Plc | Piperidine derivatives as 5-ht4 receptor antagonists |
| GB9301660D0 (en) * | 1993-01-28 | 1993-03-17 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9312348D0 (en) * | 1993-06-16 | 1993-07-28 | Smithkline Beecham Plc | Pharmaceuticals |
| IT1275903B1 (it) * | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| GB9507882D0 (en) | 1995-04-18 | 1995-05-31 | Pharmacia Spa | Substituted dihydrobenzofuran derivatives as 5-ht4 agonists |
| TW445263B (en) * | 1996-02-29 | 2001-07-11 | Janssen Pharmaceutica Nv | Novel esters of 1,4-disubstituted piperidine derivatives |
-
1997
- 1997-02-05 TW TW086101371A patent/TW445263B/zh not_active IP Right Cessation
- 1997-02-07 JP JP9530539A patent/JP2000505461A/ja not_active Ceased
- 1997-02-07 EP EP97903246A patent/EP0885190B1/en not_active Expired - Lifetime
- 1997-02-07 AT AT97903246T patent/ATE239706T1/de not_active IP Right Cessation
- 1997-02-07 US US09/125,901 patent/US6291481B1/en not_active Expired - Lifetime
- 1997-02-07 WO PCT/EP1997/000585 patent/WO1997031897A1/en not_active Ceased
- 1997-02-07 ES ES97903246T patent/ES2199341T3/es not_active Expired - Lifetime
- 1997-02-07 DE DE69721742T patent/DE69721742T2/de not_active Expired - Lifetime
- 1997-02-07 KR KR1019980705718A patent/KR100485148B1/ko not_active Expired - Fee Related
- 1997-02-07 AU AU17678/97A patent/AU724401B2/en not_active Ceased
- 1997-02-27 AR ARP970100789A patent/AR006518A1/es active IP Right Grant
- 1997-02-27 ZA ZA971735A patent/ZA971735B/xx unknown
- 1997-02-28 ID IDP970620A patent/ID17758A/id unknown
- 1997-02-28 MY MYPI97000829A patent/MY121632A/en unknown
-
2001
- 2001-08-20 US US09/933,094 patent/US6509339B2/en not_active Expired - Lifetime
-
2002
- 2002-11-19 US US10/299,317 patent/US6800628B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| TW445263B (en) | 2001-07-11 |
| US6291481B1 (en) | 2001-09-18 |
| US6800628B2 (en) | 2004-10-05 |
| US20020042430A1 (en) | 2002-04-11 |
| ZA971735B (en) | 1998-08-27 |
| KR19990082000A (ko) | 1999-11-15 |
| AU724401B2 (en) | 2000-09-21 |
| ES2199341T3 (es) | 2004-02-16 |
| DE69721742T2 (de) | 2004-03-11 |
| ATE239706T1 (de) | 2003-05-15 |
| KR100485148B1 (ko) | 2006-05-03 |
| EP0885190A1 (en) | 1998-12-23 |
| ID17758A (id) | 1998-01-22 |
| WO1997031897A1 (en) | 1997-09-04 |
| US20030153573A1 (en) | 2003-08-14 |
| EP0885190B1 (en) | 2003-05-07 |
| AU1767897A (en) | 1997-09-16 |
| MY121632A (en) | 2006-02-28 |
| DE69721742D1 (de) | 2003-06-12 |
| JP2000505461A (ja) | 2000-05-09 |
| US6509339B2 (en) | 2003-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR006518A1 (es) | Esteres de derivados de 1,4-piperidina disustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y un procedimiento para su preparacion | |
| AR013361A1 (es) | BENZAMIDAS BICíCLICAS DE DERIVADOS 3-o4-SUBSTITUíDOS DE 4-(AMINOMETIL)- PIPERIDINAS, PROCEDIMIENTO PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, PROCEDIMIENTO PARA SU PREPARACIoN, COMPUESTO INTERMEDIARIO Y PROCEDIMIENTO PARA SU PREPARACIoN. | |
| MY121852A (en) | 4-(aminoethyl)-piperidine benzamides for treating gastrointestinal disorders | |
| LTIP846A (en) | N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2h-benzopyran)carboxamide derivatives,processes for the preparation thereof and pharmaceutical compositions | |
| RU2008112290A (ru) | Производные пиридазинона, используемые для лечения боли | |
| ES2155535T3 (es) | Inhibidores de sintesis de apoliproteina b. | |
| CO4910141A1 (es) | DERIVADOS DE 1-H-PIRIDO[3,4-b]INDOL-4-CARBOXAMIDA Y SU PREPARACION | |
| AR002025A1 (es) | Derivados de 4-(1h-indol-1-il)-1-piperidinilo, su uso y un procedimiento para su preparacion, una composicion farmaceutica que los contiene, unprocedimiento para la preparacion de dicha composicion farmaceutica. | |
| AR033942A1 (es) | Compuestos de monofluoroalquilo aplicables en la potenciacion de los compuestos intermediarios utilizables en la sintesis de dichos compuestos de monofluoralquilo; composiciones farmaceuticas formuladas con dichos compuestos potenciadores y metodos para la potenciacion de las funciones de dichos rec | |
| AR035311A1 (es) | Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
| AR002984A1 (es) | Derivados de 1,3-dihidro-2h-imidazol-2-ona, procedimiento para su preparacion, composicion que los comprende, procedimiento para preparar dicha composicion y el uso de dichos derivados para fabricar medicamentos. | |
| AR009987A1 (es) | Derivados de beta-tiopropionilaminoacidos, composiciones farmaceuticas que incluyen dichos derivados, procedimiento para prepararlos, uso de dichosderivados para el tratamiento de infecciones bacterianas y compuestos intermediarios de aplicacion en dicho procedimiento | |
| CA2242494A1 (en) | Novel n-substituted 4-((4'-aminobenzoyl)-oxymethyl)-piperidines having gastric prokinetic properties | |
| OA09114A (fr) | Nouveaux dérivés hétéroarotinoïdes, leurs procédés de préparation et les compositions pharceutiques qui les contiennent. | |
| AR005834A1 (es) | Esteres de derivados de 3-hidroxipiperidinmetanol, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, un procedimiento para preparar dicha composicion, un compuesto intermediario y un proceso para preparar un compuesto intermediario. | |
| CO4750648A1 (es) | 5-naftalen-1-il-1,3 dioxanos, su preparacion y composiciones farmaceuticas que los contienen | |
| CO4970750A1 (es) | BENZAMIDAS BICICLICAS DE DERIVADOS 3-o 4-SUBSTITUIDOS 4- (AMINOMETIL)-PIPERIDINAS | |
| CA2235133A1 (en) | Esters of 3-hydroxy-piperidinemethanol derivatives | |
| ES8703453A1 (es) | Un procedimiento para preparar derivados de bencimidazol | |
| ECSP993066A (es) | Derivados de fenil esteres de alfa- aminoacidos y su uso como hipnoticos para la induccion y mantencion de la anestesia general | |
| RU96108234A (ru) | Уретан-содержащие аминостероидные соединения | |
| CO4230089A1 (es) | Derivados inotropicos y lusitropicos positivos de pirrolo- quinona, composicones farmaceuticas que los contienen y pro- cedimiento para su fabricacion | |
| ECSP003774A (es) | Derivados de espiro 2h-1-benzopiran-2,4¿-piperidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |